Sleep apnea

Studies·Oct 26, 2026·4 min read

Retatrutide cut sleep apnea events by up to 24 per hour over placebo

Two phase 3 trials tested retatrutide for obstructive sleep apnea. At 80 weeks, the 9 mg dose was linked to 24 fewer apnea events per hour than placebo in people without type 2 diabetes.